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Abstract
Background: Progressive multifocal leukoencephalopathy (PML) 
is a demyelinating disease of the central nervous system, associ-
ated with immunosuppression states. As there are only some non-
published documents concerning PML in HIV infected patients in 
Portugal, we pretend to characterize natural history of PML infec-
tion in a population of HIV patients.
Methods: We retrospectively reviewed, from 1992 to 2009, PML 
cases in a population of 724 HIV infected patients followed in our 
institution.  Clinical,  biological,  imagery  features  and  outcomes 
were characterized.
Results: Twenty-five (3.45%) patients were identified as having 
PML. The mean time between HIV and PML diagnosis was 20.4 
months. PML was the presentation of HIV infection in 40% of the 
patients, and 92% had CD4 T cell count lower than 200/mm3. Pa-
resis was the most common clinical presentation. No specific char-
acteristics were found in cerebrospinal fluid and JCV DNA was 
positive in 3 of 7 patients. MRI revealed characteristic findings. 
Combined antiretroviral therapy was started or changed in 96% 
of the patients. Neurological condition got worse in 12 patients. 
From the 14 deaths, 5 were directly attributed to PML progression. 
Follow-up was lost in 8 patients.
Conclusions: PML was the presentation of HIV infection in more 
than 1/3 of patients, frequently associated with advanced immuno-
compromise. MRI sensitivity to PML is high, and JCV DNA deter-
mination in CSF was not revealed to be sensible. PML diagnosis 
should be taken into account in HIV patients presenting any neuro-
logical symptoms, and HIV infection should be suspected when ra-
diological findings suggest PML lesions even in previously healthy 
individuals.
Keywords:  Progressive multifocal leukoencephalopathy; JC virus; 
Human immunodeficiency virus; Demyelinating disease
Introduction
Progressive  multifocal  leukoencephalopathy  (PML)  is  a 
virus-induced demyelinating disease of the central nervous 
system, first described in 1958 by Astrom et al [1]. It has 
been  described  in  different  immune  compromised  states, 
typically with suppressed cellular immunity. It also occurs in 
immunosuppressed patients while in treatment to lymphoma 
and solid organ malignancies, solid organ transplant recipi-
ents, rheumatologic diseases and a variety of diseases under 
biologic treatment like natalizumab or rituximab [2-5]. In the 
1980s, PML became an AIDS defining illness, and it is be-
lieved that nowadays 80% or more of reported PML patients 
are HIV positive [6, 7].
PML arises in a patient previously infected with John 
Cunningham virus (JCV), a polyomavirus. Primary infec-
tion occurs commonly during childhood or adolescence, and 
adult seroprevalence for JCV varies between 50 to 90% [8-
10]. During immunosuppression, JCV can reactivate, result-
ing in lytic infection of oligodendrocytes in the brain and 
abortively infects astrocytes. Oligodendrocyte death results 
in demyelination and consequently a form of disease presen-
tation that varies between patients, depending on the location 
of the underlying lesions [11]. Clinical presentation may be 
an insidious onset of cognitive impairment, weakness, visual 
field abnormalities, dysarthria, gait ataxia, dysphagia, pe-
ripheral neuropathy, dementia, seizures, behavioural chang-
es and variable degrees of paresis [2, 9, 11, 12].
PML diagnosis relies on clinical presentation, neuroim-
aging, detection of JCV DNA in cerebrospinal fluid (CSF) 
and, eventually, in histological features whenever a stereo-
tactic biopsy is done. Magnetic resonance imaging (MRI) 
is the gold standard neuroimaging diagnostic tool, showing 
typically high signal intensity areas on T2w sequence and 
low intensity areas on T1w sequence, without enhancement 
post  intravenous  contrast  injection  [13].  The  presence  of 
JCV DNA in the central nervous system (CNS), demonstrat-
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ed by PCR technique, can make the final diagnosis when the 
clinical presentation and imagery are typical, although there 
is evidence that JCV can be found in CSF of HIV infected 
patients without PML [14, 15]. Cortical demyelinating le-
sions are an integral component of the pathologic process in 
PML, and the findings in brain biopsy of bizarre astrocytes 
make the final diagnosis [7, 11].
PML in HIV infected patients has a poor prognosis, and 
continues to be one of the deadliest opportunistic infections. 
Treatment of these patients remains on highly active antiret-
roviral therapy (HAART), based on the evidence that lower-
ing viral HIV load, and consequently giving rise to the CD4 
count, will conduct to a more effective immune defense of 
the host. The outcome of the patients with PML in the setting 
of HIV is better when HAART is started [16-18]. When as-
sociated with HAART, cidofovir might improve the outcome 
of the patients [19].
The aim of the study was to analyze the natural history 
of PML in HIV infected patients followed in our institution, 
from the clinical presentation features to the outcomes.
Patients and Methods
We retrospectively reviewed an HIV population followed in 
our hospital between 1992 and 2009, identified as having had 
PML. Diagnosis of PML was based on clinical presentation, 
imaging, JCV PCR in CSF and biopsy findings whenever 
done. Data was collected as follows: HIV load, CD4 count, 
time between HIV and PML diagnosis, CSF biochemical and 
cytological characteristics, previous AIDS defining diseases, 
clinical presentation, imagery findings, CSF JCV PCR, brain 
biopsy,  therapy  instituted  and  clinical  course.  Statistical 
analysis was computed in SPSS version 17.0.
 
Results
Twenty-five  patients  were  considered  eligible,  as  having 
had PML in the context of HIV infection, collected from a 
population of 724 HIV positive patients. Four were female 
(16%) and 21 were male (84%). HIV route of transmission 
was mainly sexual (56% of patients), followed by intrave-
nous drug abuse (40%). In one patient, HIV transmission 
was attributed to bone marrow (BM) transplant in 1984. All 
of the 25 patients were infected with the HIV-1, and one of 
them had also concomitant HIV-2 infection. Eight patients 
(32%) were co-infected with HCV. The mean age at HIV di-
agnosis was 36.4 years. On average, 20.4 months after HIV 
diagnosis, the patients were diagnosed with PML, but with a 
median time of 0.75 months, due to the fact that there were 
cases (11 patients) with both diagnoses being made simulta-
neously (in 44% of the cases). 
CD4 count was always available at the time of HIV di-
agnosis. Mean CD4 count at the time of PML presentation 
was of 122/mm3, but a notion of a consistent lower immu-
nosuppression state is expressed by a median of 73/mm3. 
Twenty-three patients had CD4 count lower than 200/mm3 
and two patients had CD4 count above 500/mm3. Only pa-
tients with PML diagnosis after 1997 (10) had HIV viral load 
determined, with a mean of 117951 copies/µl. Only one had 
less than 50 copies/ml. Six patients were under any sort of 
antiretroviral therapy.
Clinical  presentation  varied  between  patients,  as  ex-
pressed in Table 1. Motor disorders with paresis were the 
most common feature presentation (72%), and mainly uni-
lateral (88.9%). Speech disorders (dysarthria, dysphasia and 
dyspraxia) and cognitive and behavioural disturbance fol-
lowed motor disturbance, in 36% and 24% of the patients, 
respectively.
Lumbar  punction  was  done  in  19  patients.  Cytology 
was done in all of them and biochemistry with glucose and 
protein analysis in 18 patients. In 6 patients leukocyte count 
was above the normal value, and always due to mononuclear 
cells. Only one patient was found to have low glucose CSF 
levels, and six patients, high protein levels. In all of the 19 
patients that underwent CSF analysis, Gram stain was nega-
tive as was the cultural exam. JCV was searched only once in 
6 patients, being positive in 2 of them. In another patient, the 
first four out of five determinations were negative.
All patients had brain-CT, showing hypodense lesions in 
the cerebral white matter, with lack of contrast enhancement 
in 88% of the cases.
Brain MRI was done in 16 patients, in all confirming 
the diagnosis, presenting characteristic findings, with T2-
weighted hyperintense lesions in cerebral white matter, with 
hypoattenuated corresponding lesions in T1-w. The three pa-
tients with normal Brain CT scans had abnormalities in MRI, 
one of them with definite PML diagnosis.
Only four brain biopsies were done (patients 15, 20, 22 
and 23), showing abundant macrophages, bizarre astrocytes 
and with nuclear inclusions in some of the cells, all samples 
compatible with PML diagnosis. In one of the patients (pt 
15), in spite of definite PML diagnosis based on the histo-
logical finding, PCR in CSF was negative.
Therapy was continued, changed or initiated in 24 pa-
tients by the time of PML diagnosis. Before 1995 all diagno-
sis but one were treated with zidovudine (AZT). Age at the 
time of HIV and PML diagnosis, before and after introduc-
tion of cARV is expressed in Table 2.
After 1997, in spite of therapy started (or continued), in 
10 patients there was a worsening of the clinical condition. 
Total recovery of the neurological deficits happened in only 
two patients (one died in a car accident, another was alive 
after 135 months of follow-up). Fourteen patients are known 
to be already dead, 5 of them due to PML progression, the 
others were attributed to other infections, mainly respiratory. 
Eight patients were lost in the follow-up.
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Discussion
  
In  this  case  series  we  describe  twenty-five  HIV  patients 
diagnosed with PML from 1992 to 2009 among 724 HIV 
patients, representing a PML prevalence, in the population 
considered, of 3.45%, concordant to that described in the lit-
erature [11, 12, 20]. 
HIV route of transmission of our patients is similar to 
that reported by the Portuguese National Coordination for 
HIV infection/AIDS till the end of the year 2009: 40% by 
intravenous drug use and 56% by sexual route [21]. 
PML diagnosis was the presentation of HIV infection in 
eleven (44%) patients. The median CD4 count in our popu-
lation was 73/mm3, similar to that described in recent retro-
spective large studies [22]. In spite of that, two patients had 
a CD4 count above 500/mm3 - although a rare finding, it 
has already been previously described [23]. In one of those 
patients, PML diagnosis was probable and, in the other one, 
it was necessary to perform several lumbar punctions before 
a positive result appeared. It may be justified because tech-
niques for determination of JCV PCR are less sensitive in 
patients under cARV [24].
Clinical  features  are  quite  different  between  patients 
and, although motor disorders were the most common find-
ings, neurological presentation varied according to the cere-
bral region most affected by JCV infection, as expressed by 
imagery. As expected, CSF analysis, when performed, did 
not reveal any specific characteristics [25, 26]. JCV DNA 
determination by PCR was done in 7 patients, being posi-
tive in three of them (42.9%). There was a false negative de-
termination in a patient with characteristic findings in MRI 
and histological confirmation of JCV infection. In seems that 
the analysis for JCV DNA early in the course of the disease 
may sometimes show a negative result, and that with lower 
immunological states, the probability of having a positive 
result for JCV DNA in CSF is higher [15, 26]. Three patients 
that were JCV positive had a CD4 count scarcely elevated 
than those that were JCV negative. Probably, using tech-
niques of real-time PCR, and rising the cycling in the proto-
col, detection level of JCV DNA would be higher, elevating 
the sensitivity of the exam and diminishing the number of 
false negatives.
All the patients underwent a CT scan, and MRI was done 
in sixteen of them. Three CT scans were normal, but MRI 
showed characteristic findings of T2-weighted hyperintense 
lesions in cerebral white matter, with hypoattenuated corre-
sponding lesions in T1-w, without mass effect, even in those 
patients in which CT scan was normal. MRI is the preferred 
imagery diagnostic tool for JCV infection, showing specific 
signs [13].
Antiretroviral  therapy  has  been  changing  dramati-
cally since late 1990s. This retrospective study also shows 
an historic perspective of antiretroviral therapy in Portugal 
(as it was in the most western countries). AZT was the first 
antiviral agent used for HIV treatment, and it is still used 
nowadays. It is still recommended as one of the agents to be 
included in therapeutic scheme due to its good penetration 
in CNS.
In pre-HAART era (before 1997), 3 patients diagnosed 
with PML were already on AZT and continued this therapy. 
Another two patients started on AZT. Of these five patients 
treated with AZT, two were lost from follow-up and the other 
three died. Before 1997, AZT monotherapy was definitely 
not an option, as was already outlined in the early 1990s [27]. 
We noticed that age at the moment of HIV (and subse-
quently PML) diagnosis is rising in the last years (cut-off 
being the beginning of cARV era), probably due to a change 
of risk behaviours for HIV transmission, as is well described 
elsewhere [28].
Eight patients were lost in follow-up. In the remaining 
Table 2. Differences Between Pre-HAART and Post-HAART Era Concerning CD4 T Cell Count, Age of Diagnosis (PML and 
HIV) and Death Causes
Characteristic All (n = 25)
PML diagnosis
Before 1997 (n = 6) 1997 - 2009 (n = 19)
Gender 4 female, 21 male 2 female, 4 male 2 female, 17 male
CD4+ cell count at diagnosis, median (IQR), cell/µl 73 (19 - 152.5) 27 (6.75 - 114.25) 76 (34 - 173)
Age at HIV diagnosis, median (IQR), years 35.5 (30.25 - 43.0) 29 (20.75 - 34.75) 37.5 (32.75 - 45)
Age at PML diagnosis, median (IQR), years 39.0 (31.5 - 46.0) 31.5 (26.25 - 31.5) 43.0 (35.0 - 48.0)
Time between HIV and PML diagnosis, median (IQR), 
months
0.75 (0.0 - 33.25) 27.0 (2.25 - 68.5) 0.0 (0 - 3.5)
Death (all causes) 14 4 10
Death (attributed to PML progression) 5 2 (50%) 3 (30%)
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seventeen patients, five died due to PML progression, nine 
died due to other causes and only three are still alive, one of 
them with total recovery and the others with partial neuro-
logical recovery.
The  median  time  to  PML-attributable  death  was  4.2 
months, compared with 30.04 months for other-cause mor-
tality. Patients that do not respond to treatment have a rapid 
course to death with a high morbidity conferred by the pro-
gression of neurological deficits. One fragility attributed to 
this paper, due to its retrospective character, is the loss in the 
follow-up of a considerable number of patients, attributed to 
the abandonment as well as the transfer to other institutions, 
concerning the residence area of the patient, what leads to an 
incapacity to accurately extrapolate survival rates.
In conclusion, PML among HIV infected patients, in 
spite of its low prevalence, must be considered whenever an 
HIV patient presents with neurological symptoms indepen-
dently of which ones, and mainly when a lower immunosup-
pression state as expressed by a low CD4 count is known. 
When a patient presents with neurological symptoms and 
PML characteristic findings in MRI, an HIV test should be 
performed. More than one CSF sample should be performed 
to JCV DNA analysis if the first sample is negative. That 
should be done in patients under cARV, as well in those with 
high CD4 T cell count. PML is an AIDS defining illness that 
occurs more often with a CD4 count lower than 200/mm3. 
When the cause of death is PML progression, it is rapid, aris-
ing in few months, in spite of cARV started at the time of 
diagnosis. Finally, PML in the post-HAART era still leads 
to great morbimortality. It can appear even with high CD4 
counts and undetectable viremia.
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